Seeking Alpha


Send Message
View as an RSS Feed
View in4thelonghaul's Comments BY TICKER:
Latest  |  Highest rated
  • Big Step Forward For InVivo [View article]
    Thanks Jason.....
    Apr 27 09:43 AM | Likes Like |Link to Comment
  • Galena Biopharma: How Long Can Big Pharma Wait? [View article]
    Extremely well said Peter & DNAC - thanks.
    Apr 24 08:42 AM | Likes Like |Link to Comment
  • Achillion Pharmaceuticals: Hope, Hype, And Hep C [View article]
    So your take on the 1625 results out of EASL on the 21st, and the heavy selloff today (23rd-Monday)?

    >>"At of the time of the poster presentation, a total of 22 patients had completed 12 weeks of ACH-1625 plus P/R followed by 12 weeks of P/R as per response guided treatment (RGT.) All (22/22, or 100%) patients had undetectable levels of HCV RNA at the end of the 24 weeks of treatment."<<
    Apr 23 12:26 PM | Likes Like |Link to Comment
  • Galena Biopharma: How Long Can Big Pharma Wait? [View article]
    Yeah Adam - and you believe everything you are told right (?) who told you DNDN's Provenge was going to fail? Seems like you steered all the dupes who listen to you away from investing when DNDN was under $3 - and weren't you downplaying HGSI's chances way back when it was under $1??
    Apr 23 10:55 AM | 2 Likes Like |Link to Comment
  • Aastrom's Renewed Momentum And Appreciation Before Anticipated Offering [View article]
    Guess he is one of those authors who don't wish to have a dialogue with readers.
    Apr 20 12:19 AM | Likes Like |Link to Comment
  • Big Step Forward For InVivo [View article]
    And their cash position is???

    Why bother writing an article and don't bother to be thorough?
    Apr 13 10:38 AM | Likes Like |Link to Comment
  • Grid-Scale Energy Storage: Lux Predicts $113.5B Global Demand By 2017 [View article]
    Venture Phil -


    International Flow Battery Forum:
    Apr 4 07:55 PM | 1 Like Like |Link to Comment
  • Grid-Scale Energy Storage: Lux Predicts $113.5B Global Demand By 2017 [View article]
    Thx SMaturin.....indeed he did sound quite upbeat - hopefully there was a concrete reason, we sure could use some positive press.
    Apr 4 07:41 PM | 4 Likes Like |Link to Comment
  • Grid-Scale Energy Storage: Lux Predicts $113.5B Global Demand By 2017 [View article]
    Thanks for all your articles John - always look forward to them and the discussions which follow.

    Has AXPW given indications that the seemingly ever present technical production glitches have finally been satisfactorily addressed? And considering the tremendous potential of Axion's lead-carbon technology, I find it odd that JCI or an established industrial player hasn't just bought AXPW out for petty cash by now - any thoughts along these lines? It seems that were Axion to land a commercial order from NS or BMW that their recent capital raise would prove quite insufficient for ramp-up requirements as well.
    Apr 4 06:35 PM | 3 Likes Like |Link to Comment
  • Keryx: Strong Upside Potential From Perifosine [View article]
    Do they pay you for this stuff?
    Mar 30 11:34 AM | Likes Like |Link to Comment
  • Mannkind: Slow, Methodical Short Covering, Or Will It Squeeze? [View article]
    Well put my friend.....FDA is thoroughly corrupt. Sad that A.Mann wasn't aware before hand, as the there was more than ample evidence in a long history of FDA duplicity and corruption - but things are as they are...hopefully he is a bit wiser this time around.
    Jan 18 11:47 AM | Likes Like |Link to Comment
  • Vertex A Steal Based On Blockbuster Hepatitis C Drug Sales [View article]
    To the uninitiated as regards this space, check out INHX's oral treatment, compare market cap, consider the recent price your proper due diligence before jumping in. Mind you, VRTX was just downgraded and is at 2-year support at market open this day.
    Nov 8 09:31 AM | Likes Like |Link to Comment
  • 3 Contenders To Be The First Profitable Stem Cell Company [View article]
    As one poster has already can not justifiably ignore ASTM - it is in P-3 for crying out loud! Any other stem cell plays you know of which are running phase 3 trials? See, there is a HUGE difference between phase one trials and phase 3 trials. Here is a clue for you if you are going to the trouble of writing an article......why not include just a bit about the current state of company specific finances????
    Oct 11 11:04 AM | Likes Like |Link to Comment
  • Sangamo's Late Breaking, Game Changing News At ICAAC [View article]
    If the results are imprsessive enough and considering the HIV lobby's political clout...possibly they can jump straight to a P-3 trial. The big questions of course are cost/efficacy and durability, which relates directly. Hopefully we will get up to date and encouraging information regarding these issues. Haven't followed SGMO closely but, at the risk of displaying my ignorance, always wondered whether these cells can reproduce or does the approach need to some way involve the bone marrow? Important to remember that SGMO is not a one-shot wonder but has a number of irons in the fire; their IP, platform technology & business model has the potential to eventually launch SGMO into the ranks of a biotech powerhouse...this is no sprint to such status though. Last I read, the City of Hope was running a trial along similar lines, actually with what appeared to be a superior trial structure, but haven't heard anything regarding this...but then I haven't been following the company for a while. As seems so common with these small developmental biotechs, SGMO has at least one instance, in the not so distant past, of claiming plenty of running capital to last for an extended period of time only to turn around and quickly engage in a dilutive financing buyer beware of claims made by SGMO mngt.
    Sep 3 12:38 PM | Likes Like |Link to Comment
  • Human Genome Sciences Gets EU Approval for Benlysta [View article]
    Good call to wait on sales ramp, as HGSI at $12.40ish, has now cratered on speculation that July sales barely increased over June sales.....of course the company is silent. Seems to be some speculation that the target population is quite a bit smaller than the company had projected...maybe it is just getting as slow start though. Would love to see GSK just make an offer of $18 for the rest of HGSI...maybe with they sweeten it and take it for $21.
    Aug 25 02:31 PM | Likes Like |Link to Comment